AtriCure (Nasdaq:ATRC) shares are trending upward today on first-quarter results that beat the consensus forecast. Shares of ATRC ticked up 6.2% at $42.65 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.2%. The Mason, Ohio-based cardiovascular care company posted losses of […]
AtriCure Inc.
AtriCure treats first patient in stroke prevention trial
AtriCure (Nasdaq:ATRC) announced today that it treated the first patient in its left atrial appendage exclusion for stroke prevention (LeAAPS) trial. U.S. co-principal investigator Dr. Marc Gerdisch treated the first patient at Franciscan St. Francis Heart Center in Indianapolis. The prospective, randomized, blinded investigational device exemption (IDE) trial will evaluate the safety and effectiveness of […]
AtriCure beats The Street in Q3
AtriCure (Nasdaq:ATRC) shares were unchanged after hours today on third-quarter results that topped the consensus forecast. The Mason, Ohio-based cardiac ablation device company posted losses of $12.3 million. That amounts to 27¢ per share on sales of $83.2 million for the three months ended Sept. 30, 2022. AtriCure reported a massive bottom-line slide into the […]
AtriCure dips on mixed bag Q2
AtriCure (Nasdaq:ATRC) shares took a slight hit today on second-quarter results that were mixed compared to the consensus forecast. The Mason, Ohio-based cardiac ablation device company posted losses of $14.8 million, or 32¢ per share, on sales of $84.5 million for the three months ended June 30, 2022, for a slight bottom-line gain on sales […]
AtriCure treats first patient in Isolator Synergy clamp trial
AtriCure (Nasdaq:ATRC) announced today that it treated the first patient in its HEAL-IST clinical trial in Belgium. Dr. Mark LaMeir and Dr. Carlo de Asmundis treated the first patient in the HEAL-IST trial evaluating the AtriCure Isolator Synergy clamp for treating drug-refractory patients diagnosed with inappropriate sinus tachycardia (IST) at University Hospital Brussels. “Symptomatic IST […]
AtriCure launches clamp for cardiac tissue ablation
AtriCure (Nasdaq:ATRC) announced today that it launched the EnCompass Clamp as part of its Isolator Synergy ablation system. Mason, Ohio-based AtriCure received FDA 510(k) clearance for the EnCompass Clamp for the ablation of cardiac tissue during cardiac surgery to make concomitant surgical ablations more efficient. According to a news release, the platform includes parallel closure, […]
These medtech companies care a lot about research
They’re making glaucoma-treating stents, tumor-treating fields, coin-sized CGMs and more. Discover the medtech companies that spend the most on research as a percentage of revenue. The list comes from our annual Big 100 report, which examines the world’s 100 largest medical device companies and ranks them by revenue. (Check out our full Big 100 report […]
AtriCure beats The Street in Q2 results
AtriCure (NSDQ:ATRC) posted second-quarter results this week that beat the overall consensus on Wall Street. The Mason, Ohio-based company reported losses of -$16.3 million, or -36¢ per share, on sales of $71.4 million for the three months ended June 30 for a sales growth of 74.84% compared with Q2 2020. Adjusted to exclude one-time items, earnings […]
AtriCure AFib treatment device wins FDA approval
AtriCure (NSDQ:ATRC) announced today that the FDA approved its EPi-Sense system for treating long-standing persistent atrial fibrillation (Afib). Mason, Ohio-based AtriCure’s EPi-Sense system demonstrated superiority in the Hybrid AF therapy arm compared to endocardial catheter ablation alone in the Converge clinical trial, according to a news release. AtriCure’s Hybrid AF therapy is a minimally invasive […]
AtriCure names Angie Wirick as chief financial officer
AtriCure (NASDAQ:ATRC) recently announced that it has appointed Angie Wirick as chief financial officer, effective August 6. Wirick, who was VP of finance, replaces Andy Wade who is stepping down for personal reasons and will continue to serve in an advisory role through March 5, 2021. “On behalf of our team at AtriCure and our Board […]
AtriCure to raise $100m from public offering
AtriCure (NASDAQ:ATRC) said today that it commenced a public offering to issue and sell roughly $100 million worth of its common stock. The Mason, Ohio–based company — maker of treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management — said it plans to grant the underwriters of the offering a 30-day option to […]
